

AN ITALIAN RETROSPECTIVE-PROSPECTIVE OBSERVATIONAL STUDY ON THE USE OF ZANUBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (AZALEA)

First published: 20/02/2025

Last updated: 16/10/2025

Study

Ongoing

Administrative details

EU PAS number

EUPAS1000000437

Study ID

1000000437

DARWIN EU® study

No

Study countries

 Italy

Study description

This retrospective-prospective observational study is designed to collect information on the population of treatment-naive (TN) or relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL) patients treated with zanubrutinib and clinical outcome of patients who received treatment according to the legislative decree on compassionate use (cohort A, retrospective and prospective study) and to collect information on the population of CLL patients treated with zanubrutinib in clinical practice who start treatment with zanubrutinib from the beginning of the study (cohort B, prospective only study).

Study status

Ongoing

Research institutions and networks

Institutions

[BeOne Medicines](#)

[Azienda Ospedaliera Santa Maria-Terni](#)

[AORN A Cardarelli](#)

[Azienda Sanitaria Universitaria Giuliano Isontina](#)

[Ospedale di Livorno - USL Toscana Nord Ovest](#)

[Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo](#)

[Azienda ULSS3 Serenissima - Ospedale dell'Angelo](#)

A.O.U. Policlinico G.Rodolico-San Marco

ARNAS Garibaldi

ASST Sette Laghi - Ospedale di circolo e
fondazione Macchi

Policlinico Tor Vergata

IEO-Istituto Europeo di oncologia

Fondazione IRCCS Istituto Nazionale dei Tumori

Azienda Ospedaliera Sant'Anna e San Sebastiano

ASST Grande Ospedale Metropolitano Niguarda

PO Mazzoni AST Ascoli Piceno

Azienda Ospedaliero Universitaria Pisana

Azienda Ospedaliera di Cosenza

A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli

Arcispedale S. Maria Nuova Reggio Emilia

Fondazione Policlinico Universitario Agostino

Gemelli

Presidio Ospedaliero A. Tortora

Azienda Ospedaliero-Universitaria di Modena

Policlinico Umberto I - Università Sapienza

AO Cardinale G. Panico, Tricase

Policlinico di Milano Ospedale Maggiore -

Fondazione IRCCS Ca' Granda

Azienda Ospedaliero - Universitaria Maggiore della
Carità

ASST DEGLI SPEDALI CIVILI DI BRESCIA

Azienda Ospedaliera "G. Brotzu"- Cagliari

La Maddalena S.p.A.

Policlinico di Bari - Azienda Ospedaliero

Universitaria Consorziabile Policlinico

ISTITUTO ROMAGNOLO PER LO STUDIO DEI

TUMORI "DINO AMADORI" - IRST

Ospedale A. Perrino-Brindisi

Presidio Ospedaliero Villa Sofia-Cervello

P.O. Santo Spirito, ASL di Pescara

Fondazione Policlinico Universitario Campus Bio-
Medico

Arcispedale Sant'Anna, Ferrara

ASL Latina - Ospedale Santa Maria Goretti

Ospedale Policlinico San Martino, IRCCS

Azienda Ospedaliero Universitaria Careggi

Ospedale San Raffaele

Ospedali Riuniti delle Marche

AOU San Giovanni di Dio e Ruggi d'Aragona

Centro di Riferimento Oncologico (CRO) di Aviano

Azienda Ospedaliera Santa Maria della

Misericordia in Perugia

AOU Sant'Andrea

ASST Valle Olona - Presidio Ospedaliero di Busto

Arsizio

Fondazione IRCCS Policlinico San Matteo

Azienda Ospedaliera di Padova

Città della Salute e della Scienza di Torino -

Ospedale Molinette

AZIENDA OSPEDALIERA UNIVERSITARIA

POLICLINICO SANT'ORSOLA MALPIGHI (Istituto di
Ematologia e oncologia medica, L.e A. Seragnoli)

Contact details

Study institution contact

Clinical Trials BeOne Medicines
clinicaltrials@beonemed.com

Study contact

clinicaltrials@beonemed.com

Primary lead investigator

Clinical Trials BeOne Medicines

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 31/01/2024

Actual: 31/01/2024

Study start date

Planned: 01/03/2025

Actual: 26/02/2025

Date of final study report

Planned: 30/12/2029

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

BeOne Medicines Italy, S.r.l.

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Other study registration identification numbers and links

BGB-3111-MA-IT-401

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Safety study (incl. comparative)

Data collection methods:

Primary data collection

Study design:

The study will be conducted as a retrospective/prospective design.

Cohort A: Retrospective and prospective data collection

Cohort B: Prospective data collection

Main study objective:

The purposes of this study are to assess: The persistency of zanubrutinib treatment; the clinical characteristics of patients initiating treatment with zanubrutinib, the clinical outcomes of patients treated with zanubrutinib; and the safety of zanubrutinib when administered to patients with TN or R/R CLL. The primary endpoint is time to permanent discontinuation (TTD) of treatment with zanubrutinib.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name

BRUKINSA

Medicinal product name, other

BGB-3111

Study drug International non-proprietary name (INN) or common name

ZANUBRUTINIB

Anatomical Therapeutic Chemical (ATC) code

(L01EL03) zanubrutinib

zanubrutinib

Medical condition to be studied

Chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia refractory

Additional medical condition(s)

treatment-naive chronic lymphocytic leukaemia, relapsed or refractory chronic lymphocytic leukaemia

Population studied

Short description of the study population

Cohort A: patients with CLL who were enrolled and treated as part of the BeOne Medicines Compassionate Use Program, according to clinical judgment and legislative decree on compassionate uses (7 September 2017).

Cohort B: patients with a confirmed diagnosis of CLL per the iwCLL criteria, TN

or R/R, who were prescribed zanubrutinib in clinical practice, based on the standard of care criteria at the practice. A prescription for zanubrutinib must precede the patient's signature on the informed consent form.

Age groups

- **Adult and elderly population (≥ 18 years)**
 - Elderly (≥ 65 years)
-

Estimated number of subjects

350

Study design details

Outcomes

Primary: Time to permanent discontinuation (TTD) of treatment with zanubrutinib

Secondary:

- Reasons for permanent discontinuations of treatment with zanubrutinib
- Rate of discontinuations of zanubrutinib due to adverse events
- Cumulative incidence of treatment discontinuation according to reasons (i.e. PD, AEs, etc)
- Modality of treatment with zanubrutinib (daily dose and regimen of administration, i.e. QD and BID), dose reduction and rate of permanent dose reduction
- Overall survival (OS) and survival at predetermined time points (months, 6, 12, 18, 24, end of study)
- Progression-free survival (PFS) by Kaplan-Meier method
- Response rate (iwCLL criteria)

- Health resource utilization during the study: number and rates of hospitalizations, emergency room attendance, unscheduled visits
 - Adherence to treatment (PROMIS questionnaire) at predetermined time points (months 3, 6, 9, 12, 18, 24, and every six months thereafter until end of treatment - EOT)
 - Changes from baseline in patient-reported outcomes measured by the Global health status/QoL (GHS) and physical and role functioning scales of EORTC QLQ-C30, and symptom burden and fatigue scales of EORTC QLQ-CCL17 at predetermined time points (months 3, 6, 9, 12, 18, 24, and every six months thereafter until EOT)
 - Rate of adverse drug reactions to zanubrutinib
 - Rate of serious and not serious adverse events (related and not related to zanubrutinib)
 - Changes in concomitant medications
-

Data analysis plan

Data from all patients who signed the informed consent will be used in the analysis. All statistical analyses will be performed using all data collected in the database up to the data cutoff date.

The patient disposition will be summarized from the evaluable analysis set. The reason for discontinuation will be summarized. Unless otherwise specified, the analysis will be based on the evaluable analysis set. Data will be summarized overall and by cohort (cohort A and cohort B).

Quantitative data will be described by standard descriptive statistics (eg, mean, standard deviation, minimum, and maximum), and qualitative data will be summarized by frequency tables with number and proportion in each category. A missing category will be included as applicable.

For categorical endpoints, number and proportion of patients for each category will be summarized.

Time-to-event endpoints, i.e. time to permanent discontinuation of zanubrutinib, OS and PFS, will be summarized graphically using Kaplan-Meier plots overall and for each cohort.

Two interim analyses are planned for this study. The first interim analysis will be performed in the retrospective part of cohort A, and the second interim analysis will be performed in the prospective part of cohort A and cohort B, at 6 months after the last prospective patient enrolled.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Electronic healthcare records \(EHR\)](#)

[Expanded access program \(compassionate use\)](#)

[Non-interventional study](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No